Novel symptomatology and changing epidemiology of domoic acid toxicosis in California sea lions ( <i>Zalophus californianus</i> ): an increasing risk to marine mammal health
Tracey Goldstein(Colorado State University), Frances M. D. Gulland(Marine Mammal Center), Gregg W. Langlois(California Department of Public Health), Jonna A. K. Mazet(University of California, Davis), Sophie Dennison(Marine Mammal Center), D. Clive Williams(Trinity College Dublin), Tod A. Leighfield(NOAA National Ocean Service), Fran Van Dolah(NOAA National Ocean Service), Tanja S. Zabka(Marine Mammal Center), Jerome Barakos(Sutter Health), P. A. Conrad(California Department of Public Health), Mary W. Silver(University of California, Santa Cruz), Martin Haulena(Vancouver Aquarium), K Colegrove(University of California, Davis), Sibel Bargu(University of California, Santa Cruz)
Cited by 207
Related Papers
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
|Neurology|2009|741
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
|The Lancet Neurology|2010|696
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
|JAMA Neurology|2021|602
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis
|The Lancet Neurology|2012|512
Spillover and pandemic properties of zoonotic viruses with high host plasticity
|Scientific Reports|2015|372